Free Trial
NASDAQ:RGEN

Repligen (RGEN) Stock Price, News & Analysis

Repligen logo
$124.06 +0.50 (+0.40%)
As of 02:33 PM Eastern

About Repligen Stock (NASDAQ:RGEN)

Key Stats

Today's Range
$122.62
$126.04
50-Day Range
$117.54
$145.23
52-Week Range
$102.97
$182.52
Volume
281,620 shs
Average Volume
727,347 shs
Market Capitalization
$6.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$172.83
Consensus Rating
Moderate Buy

Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

RGEN MarketRank™: 

Repligen scored higher than 95% of companies evaluated by MarketBeat, and ranked 55th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Repligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Repligen's stock forecast and price target.
  • Earnings Growth

    Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Repligen is -278.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Repligen is -278.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Repligen has a PEG Ratio of 3.54. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Repligen has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Repligen's valuation and earnings.
  • Percentage of Shares Shorted

    6.38% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 1.74%, indicating that investor sentiment is improving.
  • Dividend Yield

    Repligen does not currently pay a dividend.

  • Dividend Growth

    Repligen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.38% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 1.74%, indicating that investor sentiment is improving.
  • News Sentiment

    Repligen has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Repligen this week, compared to 9 articles on an average week.
  • Search Interest

    Only 3 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Repligen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Repligen is held by insiders.

  • Percentage Held by Institutions

    97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Repligen's insider trading history.
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"
Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Repligen: Long-Term Growth Gem Suffers Some Setbacks
Craig-Hallum Sticks to Its Buy Rating for Repligen (RGEN)
See More Headlines

RGEN Stock Analysis - Frequently Asked Questions

Repligen's stock was trading at $143.94 at the beginning of the year. Since then, RGEN stock has decreased by 12.9% and is now trading at $125.3250.
View the best growth stocks for 2025 here
.

Repligen Corporation (NASDAQ:RGEN) posted its quarterly earnings data on Tuesday, April, 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The firm's quarterly revenue was up 10.4% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and more.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
4/29/2025
Today
6/30/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
Employees
1,778
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$172.83
High Stock Price Target
$200.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+39.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
72.13
P/E Growth
3.54
Net Income
-$25.51 million
Pretax Margin
-3.53%

Debt

Sales & Book Value

Annual Sales
$634.44 million
Cash Flow
$3.12 per share
Price / Cash Flow
39.77
Book Value
$35.21 per share
Price / Book
3.52

Miscellaneous

Free Float
55,509,000
Market Cap
$6.97 billion
Optionable
Optionable
Beta
1.11

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:RGEN) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners